Key result
Sacubitril/valsartan reduces CV mortality and hospitalization ~25% vs. enalapril in HF patients.
Why the study?
The study was conducted to compare clinical outcomes between sacubitril/valsartan and enalapril in patients with heart failure.
Does sacubitril/valsartan reduce mortality and cardiovascular hospitalization compared to enalapril in patients with heart failure?
Meta-Analysis (n=14,147)
Does sacubitril/valsartan reduce mortality and cardiovascular hospitalization compared to enalapril in patients with heart failure?
Sacubitril/valsartan demonstrates superior clinical performance compared to enalapril in reducing cardiovascular mortality and hospitalizations in patients with heart failure.
Supports sacubitril/valsartan preference in heart failure; confirms meta-analytic benefits for cardiovascular outcomes.
The objective of this meta-analysis was to compare outcomes between sacubitril/valsartan and enalapril in patients with heart failure. We performed this meta-analysis according to the guidelines reported in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Two independent authors systematically searched online databases including PubMed, Cochrane Library, and Web of Science from inception till September 15, 2023. Outcomes assessed in this meta-analysis included all-cause mortality, cardiovascular mortality, and cardiovascular-related hospitalization. A total of nine studies were included in this meta-analysis. Pooled analysis showed that the risk of all-cause mortality was higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan (risk ratio [RR]: 0.57; 95% CI: 0.31 to 1.04). Risk of cardiovascular mortality was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.75; 95% CI: 0.62 to 0.91). The risk of cardiovascular hospitalization was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.76; 95% CI: 0.66 to 0.86). In conclusion, our meta-analysis of nine studies underscores the superior clinical performance of sacubitril/valsartan compared to enalapril in managing patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Reyaz et al. (2023) conducted a meta-analysis in Heart failure (n=14,147). Sacubitril/valsartan vs. Enalapril was evaluated on Cardiovascular mortality (RR 0.75, 95% CI 0.62 to 0.91). Sacubitril/valsartan significantly reduced the risk of cardiovascular mortality (RR 0.75) and cardiovascular hospitalization (RR 0.76) compared to enalapril in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: